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Abstract
Trifluoroethylarenes are found in a variety of biologically active molecules, and strategies for 
accessing this substructure are important for developing therapeutic candidates and biological 
probes. Trifluoroethylarenes can be directly accessed via nucleophilic trifluoromethylation of 
benzylic electrophiles; however, current catalytic methods do not effectively transform electron-
deficient substrates and heterocycles. To address this gap, we report a Cu-catalyzed 
decarboxylative trifluoromethylation of benzylic bromodifluoroacetates. To account for the 
tolerance of sensitive functional groups, we propose an inner-sphere mechanism of 
decarboxylation.
Graphical abstract
The trifluoromethyl group (CF3) is commonly utilized in medicinal chemistry, agricultural 
chemistry and materials sciences to modulate the physical and biological properties of 
molecules.1,2 Among trifluoromethyl-containing substructures, trifluoroethyl(hetero)arenes 
represent an important motif, with over 30,000 trifluoroethyl(hetero)arenes possessing 
documented biological activity or being precursors to bioactive compounds.3 Thus, general 
strategies for preparing this substructure are important for accessing biological probes and 
therapeutics. While several approaches for preparing this group have been reported,4 one 
direct route involves the trifluoromethylation of benzylic electrophiles; however, no general 
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catalytic system can transform a broad spectrum of (hetero)benzylic electrophiles. Current 
systems for benzylic trifluoromethylation require either stoichiometric Cu (eq 1),4b,5 or 
exclusively transform electron-neutral (eq 2)6 or electron-rich substrates (eq 3).7 Thus, a 
need remains for a catalytic system that can transform electron-deficient benzylic 
electrophiles and heterocyclic derivatives into trifluoroethyl(hetero)arenes. Herein, we 
report such a general catalytic system that enables access to a broad array of 
trifluoroethyl(hetero)arenes. Further, we propose a revised mechanism that accounts for the 
expanded functional group tolerance.
To address the aforementioned gap, we sought to develop a broadly applicable catalytic 
method for converting benzylic electrophiles into trifluoroethyl(hetero)arenes. As a starting 
point for this transformation, we considered Chen’s decarboxylative trifluoromethylation of 
benzyl bromodifluoroacetates using stoichiometric Cu.5f Beneficial features of this early 
system included: (1) facile access to substrates derived from simple benzylic alcohols, which 
are synthetically accessible and already found in a wide variety of synthetic intermediates 
and building blocks; (2) the formation of just CO2 and KBr as benign, easily separable by-
products. However, this previous transformation was not shown to convert a broad spectrum 
of substrates,5f potentially because the proposed mechanism invoked an outer-sphere 
decarboxylation that generated free −CF3 (Scheme 2).5d–f If generated, this reactive 
intermediate would react with carbonyl-based functional groups via 1,2-addition and acidic 
functional groups via deprotonation, which would severely limit the functional group 
compatibility of the transformation. However, we hypothesized that a catalytic inner-sphere 
decarboxylation might generate the critical Cu–CF3 intermediate, which would enable the 
conversion of substrates bearing sensitive carbonyl and acidic functional groups.
Rational optimization of Chen’s CuI-mediated reaction provided a system capable of 
transforming benzylic electrophiles with only catalytic quantities of Cu. Chen’s original 
reaction of 1a with stoichiometric CuI provided trifluoroethylarene 2a in 71% yield;5f 
however, according to the previous protocol, 1a was slowly added to the reaction mixture 
over 2 h, which can be labor intensive and operationally challenging for small scale 
reactions.5f To explore a more user-friendly protocol, we charged the vessel with the full 
quantity of 1a at the outset of the reaction. Using stoichiometric CuI, this procedure lowered 
the yield of 2a and formed benzylic bromide 3a as a side product (Table 1, entry 1). Given 
our aim of developing a Cu-catalyzed process, we adapted conditions that effectively 
catalyzed the decarboxylative trifluoromethylation of allylic bromodifluoroacetates (cat. 
CuI, N,N’-dimethylethylenediamine, NaO2CCF2Br, DMF).8a However, benzylic 
bromodifluoroacetates proved less reactive than their allylic counterparts, and optimization 
of our previous catalyst system provided poor yields of 2a (entry 2), along with several side 
products, generally in 2–10% yield (Bn–CF2CF3, Bn–I, Bn–F, Bn–Bn, and Bn–O2CCF3). 
Subsequent screening of various N-, O-, and P-based ligands, and attempted modulation of 
reaction parameters did not improve the transformation. Further, in many cases, addition of 
a chelating ligand impaired the reaction. Thus, we pursued a system that did not employ a 
chelating ligand. Using a DMF-ligated system, and MeO2CCF2Br as an additive,5d a modest 
yield of 2a was observed, and benzylic bromide 3a was identified as the major side-product 
(entry 3). The formation of 3a could be suppressed by replacement of DMF with MeCN, but 
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this change also afforded a less active system (entry 4). Based on these observations, we 
hypothesized that the use of a DMF/MeCN solvent mixture would provide an active system 
that would minimize the formation of 3a. Indeed, employment of a 1:1 mixture of DMF/
MeCN improved the yield of desired product 2a, and minimized formation of the benzylic 
bromide side-product 3a (entry 5).
In addition to the solvent, the presence of I− had a profound effect on the present reaction. In 
previous reports of Cu-mediated trifluoromethylation of benzylic bromodifluoroacetates, 
stoichiometric quantities of I− played an essential role in generating the desired products.5f 
In contrast, a recent Cu-catalyzed trifluoromethylation of allylic bromodifluoroacetates 
could occur in the complete absence of I−.8a Thus, for the present system, the loading of I− 
merited investigation. Addition of catalytic KI (45% total I−) provided the highest yield of 
desired product 2a, and minimized formation of benzylic bromide 3a and other side-
products (< 2% by GC and 19F NMR analysis; entry 6). In contrast, complete removal of I− 
from the system {[Cu(MeCN)4]PF6} decreased the yield of trifluoroethylarene, and 
generated additional bromide 3a (entry 7). However, the catalytic activity using 
[Cu(MeCN)4]PF6 could be restored by reintroducing 45% I− to the system (entry 6 vs. entry 
8). Further increase of the I− content beyond 45% decreased the yield of desired product 2a 
(entry 9). In addition, removal of the MeO2CCF2Br additive from the system resulted in 
decreased yield of 2a, and increased benzyl bromide 3a (entry 10). Ultimately, we selected a 
general system that employed 20% CuI, 25% KI, 40% MeO2CCF2Br and super-
stoichiometric KF in MeCN/DMF (1:1), which minimized the formation of side-products 
(<2%) and provided good yield of trifluoroethylarene 2a.
The present Cu-catalyzed reaction tolerated a broad array of useful functional groups (Table 
2), including: ethers (2b, 2e–f, 2l), a secondary amide (2c), a substituted aniline (2d), an aryl 
bromide (2e), an alkene (2h), a mesylate (2j), esters (2k, 2n), and a ketone (2m). Substrates 
bearing (pseudo)ortho substituents provided lower yields of products (2e–f, 2q–s), and a 
sterically hindered 2,6-disubstitued benzylic electrophile afforded product in modest yield 
(2g). The present reaction also tolerated heterobenzylic substrates that incorporated N, O, 
and S atoms (2o–s). When the reaction was conducted on gram-scale, the yield of the 
reaction was maintained (2b), which indicates that this process would be useful for the 
preparation of larger quantities of target trifluoroethyl(hetero)arene compounds.
The broad functional group compatibility implicates a metal-centered decarboxylation that 
does not involve solvent-separated reactive intermediates. If free in solution, −CF3 (pka = 27 
in H2O)9 would react with sensitive functional groups. However, the tolerance of carbonyls 
(2k, 2m–o) and an acidic amide (2c, pka ca. 13.8 in H2O),10 suggest that free −CF3 must not 
exist in solution.4b Additionally, in the reaction of 1m–n, 19F NMR spectra of the crude 
reaction mixtures did not show products deriving from 1,2-addition or addition-elimination 
processes. Further, the reaction of 1a was conducted in the presence of 2-naphthaldehyde 
(1.0 equiv) with minimal loss of yield (68%) and no evidence of 1,2-addition of −CF3 to the 
aldehyde, further discounting the existence of free −CF3 in solution.11 Thus, decarboxylation 
must be a process that either converts Cu–O2CCF2Br to Cu–CF3 directly at the metal-center, 
or that keeps reactive −CF3 within the solvent cage surrounding Cu. This proposed 
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mechanism likely explains the broad functional group compatibility of 
bromodifluoroacetate-mediated trifluoromethylation reactions.8
Circumstantial evidence implicates that, as previously suggested,5f the present reaction may 
involve in situ conversion of Bn–O2CCF2Br to a Bn–I intermediate prior to 
trifluoromethylation. First, the catalytic system required I− for turnover, and added I− 
facilitated the transformation (vide supra). Second, a steady-state concentration of Bn–I 
persisted throughout the course of the reaction, and the experiment conducted with KI 
showed higher [Bn–I] than the experiment conducted without KI.11 Third, the electronic 
nature of the arene ring noticeably perturbed the reactivity of the substrates, with electron-
rich substrates (2b–f) providing higher yields than electron-neutral (2i–l) and electron-
deficient substrates (2j–k). The latter trend may suggest that the benzylic position develops 
cationic character at a transition state of the reaction, which may implicate a SN1- or SN2-
like step in the mechanism. Based on these pathways, the more slowly reacting electron-
deficient electrophiles may allow decomposition of Cu–CF312 to compete with productive 
trifluoromethylation, thus providing decreased yields for the e−-deficient substrates. 
Combined, these data fit a mechanism in which Bn–O2CCF2Br converts to Bn–I, prior to 
undergoing trifluoromethylation (Figure 1). Further, the added I− may play an additional 
role by converting the less reactive Bn–Br side product into a more active Bn–I electrophile. 
Regardless, the loading of I−enabled optimal performance of the catalytic system, and for 
any given substrate, future users may wish to optimize the loading of I−.
To illustrate the utility of this protocol, the Cu-catalyzed decarboxylative 
trifluoromethylation of benzylic bromodifluoroacetates was applied to an intermediate in the 
synthesis of a fluorinated Tebufenpyrad analogue possessing acaricidal activity (Scheme 3). 
In a previous report, alcohol 3 was transformed into fluorinated intermediate 5 through a 4-
step procedure that employed stoichiometric Mn and Sn and afforded product in 31% overall 
yield.13 In contrast, the present 2-step procedure converted 3 to 5 in 60% total yield utilizing 
catalytic Cu. Thus, the present protocol demonstrated several desirable traits including: 1) 
improvement of overall yield of trifluoroethylheteroarene; 2) avoidance of oxidation and 
reduction reactions; 3) decrease in time and resource costs; 4) reduction of metal-containing 
waste products (stoichiometeric Mn and Sn vs. catalytic Cu). These attractive features 
should be useful for both agricultural and medicinal chemists.
CONCLUSION
In conclusion, two key features, solvent and I−, enabled a Cu-catalyzed decarboxylative 
trifluoromethylation of benzylic and heterobenzylic bromodifluoroacetates. This 
transformation provided trifluoroethylarenes and heteroarenes from readily available 
alcohols through a simple and robust two-step procedure. The protocol transformed a variety 
of benzylic bromodifluoroacetates, including electron-deficient and heterocyclic substrates, 
and substrates bearing carbonyl groups and acidic protons. The expanded functional group 
compatibility is rationalized by a metal-centered decarboxylation event, which does not 
seem to generate free −CF3 in solution. We envision that this system will be useful for 
accessing biological probes, therapeutic agents, and agrochemicals. Ongoing work in our 
laboratory aims to use decarboxylative strategies to address related challenges in synthetic 
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organofluorine chemistry, such as the conversion of unactivated electrophiles to 
trifluoromethanes.
EXPERIMENTAL SECTION
Unless otherwise noted, reactions were performed using oven-dried glassware under an 
atmosphere of dry N2. Trifluoromethylation reactions were performed in resealable 15 mL 
test tubes sealed with PTFE septa. All other reactions were performed in round-bottom 
flasks, which were sealed with rubber septa. Stainless steel syringes were used to transfer 
air- or moisture-sensitive liquid reagents. Reactions were monitored by thin-layer 
chromatography (TLC) on UNIPLATE™ Silica Gel HLF 250 micron glass plates precoated 
with 230–400 mesh silica impregnated with a fluorescent indicator (250 nm), visualizing by 
quenching of fluorescence, KMnO4 solution, or p-anisaldehyde solution. Silica gel for 
chromatographic purifications was purchased from Sorbent Technologies (cat. #30930M-25, 
60 Å, 40–63 µm).
Commercial reagents were purchased and used as received with the following exceptions. 
Anhydrous potassium fluoride (KF) and potassium iodide (KI) were dried in a vacuum-oven 
at 200 °C for 24 h and stored in a N2 filled glovebox. Use of non-anhydrous KF resulted in 
decreased yields of desired products. In the absence of a glovebox, comparable yields were 
obtained by flame-drying KF and KI under vacuum, and using standard Schlenk techniques. 
Anhydrous N,N′-dimethylformamide (DMF), acetonitrile (MeCN), methanol (MeOH), 
dichloromethane (DCM), tetrahydrofuran (THF), and triethylamine (NEt3) were dispensed 
from a solvent purification system, in which the solvent was dried by passage through two 
columns of activated alumina under argon. Some benzylic alcohols were acquired by 
reduction of the corresponding aldehydes using NaBH4 (1.5 equiv) in anhydrous MeOH at 0 
°C or the corresponding carboxylic acid using lithium aluminum hydride (2.0 equiv) at 0 °C.
Proton nuclear magnetic resonance (1H NMR) spectra were recorded at 400 or 500 MHz. 
Carbon nuclear magnetic resonance (13C NMR) spectra were recorded at 101 or 126 MHz. 
Fluorine nuclear magnetic resonance (19F NMR) spectra were recorded at 376 MHz. 
Chemical shifts (δ) for protons are reported in parts per million (ppm) downfield from 
tetramethylsilane, and are referenced to the proton resonance of residual CHCl3 in the NMR 
solvent (δ = 7.27 ppm). Chemical shifts (δ) for carbon are reported in parts per million 
downfield from tetramethylsilane, and are referenced to the carbon resonances of the solvent 
peak (δ = 77.16 ppm). Chemical shifts (δ) for fluorine are reported in parts per millions, and 
are referenced to PhCF3 (δ = −63.72 ppm). NMR data are represented as follows: chemical 
shift (ppm), multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, sept = septet, m = 
multiplet), coupling constant in Hertz (Hz), and integration.
Exact mass determinations were obtained by the following methods; electron impact 
ionization (EI) using a magnetic and electrostatic sector mass analyzer, electrospray 
ionization (ESI) using a TOF mass analyzer, or atmospheric-pressure chemical ionization 
(APCI–hexane/PhMe) using a QTOF mass analyzer, for which sample plus near mass 
internal exact mass standard were dissolved in hexane, and hexane or PhMe/hexane were 
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used as ionization solvent. Melting points were uncorrected and measured on a Thomas 
Hoover Capillary Melting Point Apparatus.
General Procedure A
HO2CCF2Br (1.45 equiv) was added to a round-bottom flask, which was sealed with a 
rubber septum and attached to an oil bubbler. DCM and DMF were injected, and the 
solution was cooled to 0 °C. Oxalyl chloride (1.4 equiv) was injected (caution: evolution of 
noxious gas), and after 5 min, the mixture was allowed to warm to rt. After 2 h, the mixture 
was cooled to 0 °C, and a solution of benzylic alcohol (1.0 equiv) and NEt3 (2–3 equiv) in 
DCM was added. The reaction was monitored by TLC analysis, and after consumption of 
the benzylic alcohol (usually within 1–2 h), the reaction was quenched with water, and the 
aqueous layer was extracted with DCM or EtOAc (4x). The combined organic layers were 
washed with brine, dried over Na2SO4, and filtered. After the removal of solvent, the residue 
was purified by flash column chromatography to afford bromodifluoroacetates 1a–s.
4-Methylbenzyl 2-bromo-2,2-difluoroacetate (1a)—General Procedure A was 
followed using 4-methylbenzyl alcohol (1.5 g, 12 mmol). Workup and chromatographic 
purification (hexanes) afforded the title compound as a colorless oil (2.9 g, 87%). 1H NMR 
(400 MHz, CDCl3) δ 7.31 (d, J = 8.0 Hz, 2 H), 7.22 (d, J = 7.9 Hz, 2 H), 5.33 (s, 2 H), 2.38 
(s, 3 H). 19F NMR (376 MHz, CDCl3) δ −60.72 (s, 2 F). Spectroscopic data are consistent 
with the previous report.5f
4-(Benzyloxy)benzyl 2-bromo-2,2-difluoroacetate (1b)—General Procedure A was 
followed using 4-(benzyloxy)benzyl alcohol (0.65 g, 3.0 mmol). Workup and 
chromatographic purification (hexanes/EtOAc, 1:0→19:1) afforded the title compound as a 
colorless solid (0.88 g, 79%). mp 64–65 °C. 1H NMR (400 MHz, CDCl3) δ 7.51–7.31 (m, 7 
H), 7.01 (d, J = 8.4 Hz, 2 H), 5.31 (s, 2 H), 5.10 (s, 2 H). 13C{1H} NMR (101 MHz, CDCl3) 
δ 159.7, 159.6 (t, J = 31.6 Hz), 136.7, 130.8, 128.8, 128.3, 127.6, 125.9, 115.2, 108.9 (t, J = 
314.5 Hz), 70.2, 69.9. 19F NMR (376 MHz, CDCl3) δ −60.7 (s, 2 F). HRMS (EI): m/z [M]+ 
calcd for C16H13BrF2O3: 370.0016; found: 370.0012 (1.1 ppm). IR (film): 2945, 2866, 
1769, 1609, 1585, 1518, 1454, 1302, 1246, 1161, 1126, 1018, 955, 870, 814, 742, 706, 613 
cm−1.
4-Pivalamidobenzyl 2-bromo-2,2-difluoroacetate (1c)—General Procedure A was 
followed using N-[4-(hydroxymethyl)phenyl] pivalamide (0.83 g, 4.0 mmol). Workup and 
chromatographic purification (hexanes/EtOAc, 1:0→25:4) afforded the title compound as a 
yellow solid (1.2 g, 85%). mp 86–87 °C. 1H NMR (400 MHz, CDCl3) δ 7.61–7.56 (m, 2 H), 
7.42 (s, 1 H), 7.39–7.34 (m, 2 H), 5.31 (s, 2 H), 1.32 (s, 9 H). 13C{1H} NMR (101 MHz, 
CDCl3) δ 176.9, 159.5 (t, J = 31.4 Hz), 139.1, 129.9, 129.1, 120.2, 108.8 (t, J = 314.3 Hz), 
69.6, 39.8, 27.7. 19F NMR (376 MHz, CDCl3) δ −60.8 (s, 2 F). HRMS (APCI–hexane/
PhMe): m/z [M+H]+ calcd for C14H17BrF2NO3: 364.0360; found: 364.0362 (0.5 ppm). IR 
(film): 3292, 2975, 1771, 1655, 1599, 1520, 1460, 1294, 1157, 955, 820, 700, 604 cm−1.
3-(Dibenzylamino)benzyl 2-bromo-2,2-difluoroacetate (1d)—General Procedure A 
was followed using [3-(dibenzylamino)phenyl]methanol (0.83 g, 4.0 mmol). Workup and 
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chromatographic purification (hexanes/EtOAc, 1:0→21:4) afforded the title compound as a 
yellow solid (1.2 g, 85%). mp 67–68 °C. 1H NMR (400 MHz, CDCl3) δ 7.41–7.34 (m, 4 H), 
7.33–7.25 (m, 6 H), 7.25–7.18 (m, 1 H), 6.80–6.72 (m, 3 H), 5.27 (s, 2 H), 4.71 (s, 4 
H). 13C{1H} NMR (101 MHz, CDCl3) δ 159.5 (t, J = 31.4 Hz), 149.6, 138.2, 134.6, 129.8, 
128.9, 127.2, 126.7, 116.6, 113.1, 111.9, 108.8 (t, J = 314.3 Hz), 70.3, 54.3. 19F NMR (376 
MHz, CDCl3) δ −60.7 (s, 2 F). HRMS (APCI–hexane/PhMe): m/z [M]+ calcd for 
C23H20BrF2NO2: 459.0645; found: 459.0644 (0.2 ppm). IR (film): 3028, 2866, 1774, 1605, 
1582, 1495, 1452, 1294, 1167, 1122, 953, 775, 733, 694 cm−1.
2-Bromo-3,4-dimethoxybenzyl 2-bromo-2,2-difluoroacetate (1e)—General 
Procedure A was followed using (2-bromo-3,4-dimethoxyphenyl) methanol14 (0.94 g, 3.8 
mmol). Workup and chromatographic purification (hexanes/EtOAc, 1:0→9:1) afforded the 
title compound as a viscous, colorless oil [1.3 g, 83% (after correction for 10 mol% solvent 
impurity)]. 1H NMR (400 MHz, CDCl3) δ 7.20 (d, J = 8.5 Hz, 1 H), 6.90 (d, J = 8.5 Hz, 1 
H), 5.41 (s, 2 H), 3.90 (s, 3 H), 3.88 (s, 3 H). 13C{1H} NMR (126 MHz, CDCl3) δ 159.4 (t, J 
= 31.5 Hz), 154.6, 147.1, 126.5, 125.8, 120.2, 111.2, 108.8 (t, J = 314.4 Hz), 69.6, 60.7, 
56.3. 19F NMR (376 MHz, CDCl3) δ −60.61 (s, 2 F). HRMS (APCI–hexane/PhMe): m/z 
[M]+ calcd for C11H10Br2F2O4: 401.8914; found: 401.8910 (1.0 ppm). IR (film): 2943, 
2839, 1772, 1595, 1493, 1410, 1296, 1122, 1036, 941, 806, 750, 702 cm−1.
2-(Benzyloxy)benzyl 2-bromo-2,2-difluoroacetate (1f)—General Procedure A was 
followed using [2-(benzyloxy)phenyl]methanol (0.70 g, 3.3 mmol). Workup and 
chromatographic purification (hexanes/EtOAc, 1:0→19:1) afforded the title compound as a 
colorless solid (1.1 g, 88%). mp 45–46 °C. 1H NMR (400 MHz, CDCl3) δ 7.48 – 7.32 (m, 7 
H), 7.05 – 6.97 (m, 2 H), 5.49 (s, 2 H), 5.16 (s, 2 H). 13C{1H} NMR (101 MHz, CDCl3) δ 
159.6 (t, J = 31.3 Hz), 157.1, 136.7, 130.8, 130.5, 128.7, 128.2, 127.3, 122.3, 120.9, 112.1, 
108.9 (t, J = 314.5 Hz), 70.2, 65.9. 19F NMR (376 MHz, CDCl3) δ −60.44 (s, 2 F). HRMS 
(EI): m/z [M]+ calcd for C16H13BrF2O3: 370.0016; found: 370.0023 (1.9 ppm). IR (film): 
3034, 1774, 1605, 1498, 1452, 1379, 1296, 1250, 1165, 1126, 1024, 949, 806, 754, 696 
cm−1.
2,4,6-Trimethylbenzyl 2-bromo-2,2-difluoroacetate (1g)—General Procedure A was 
followed using mesitylmethanol (0.60 g, 4.0 mmol). Workup and chromatographic 
purification (hexanes/EtOAc, 1:0→19:1) afforded the title compound as a colorless solid 
(1.1 g, 88%). mp 45–46 °C. 1H NMR (500 MHz, CDCl3) δ 6.92 (s, 2 H), 5.45 (s, 2 H), 2.39 
(s, 6 H), 2.31 (s, 3 H). 13C{1H} NMR (126 MHz, CDCl3) δ 159.9 (t, J = 31.2 Hz), 139.7, 
138.7, 129.4, 126.9, 108.9 (t, J = 314.7 Hz), 65.2, 21.2, 19.6. 19F NMR (376 MHz, CDCl3) δ 
−60.51 (s, 2 F). HRMS (APCI–hexane/PhMe): m/z [M]+ calcd for C12H13BrF2O2: 
306.0067; found: 306.0080 (4.2 ppm). IR (film): 3011, 2974, 2957, 2922, 2866, 1772, 1614, 
1583, 1448, 1375, 1302, 1288, 1167, 1126, 1032, 951, 912, 851, 771, 700 cm−1.
(E)-4-Styrylbenzyl 2-bromo-2,2-difluoroacetate (1h)—General Procedure A was 
followed using (E)-(4-styrylphenyl) methanol15 (0.72 g, 3.4 mmol). Workup and 
chromatographic purification (hexanes) afforded the title compound as a colorless solid (1.1 
g, 86%). mp 75–76 °C. 1H NMR (400 MHz, CDCl3) δ 7.56 (t, J = 7.5 Hz, 4 H), 7.45–7.36 
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(m, 4 H), 7.34–7.28 (m, 1 H), 7.21–7.09 (m, 2 H), 5.38 (s, 2 H). 13C{1H} NMR (101 MHz, 
CDCl3) δ 159.6 (t, J = 31.6 Hz), 138.5, 137.1, 132.6, 129.9, 129.2, 128.9, 128.1, 127.9, 
127.0, 126.8, 108.9 (t, J = 314.4 Hz), 69.7. 19F NMR (376 MHz, CDCl3) δ −60.7 (s, 2 F). 
HRMS (APCI–hexane/PhMe): m/z [M]+ calcd for C17H13BrF2O2: 366.0067; found: 
366.0055 (3.3 ppm). IR (film): 3026, 1772, 1514, 1448, 1383, 1296, 1165, 1126, 966, 949, 
866, 818, 704, 690 cm−1.
Naphthalen-2-ylmethyl 2-bromo-2,2-difluoroacetate (1i)—General Procedure A 
was followed using (naphthalen-2-yl)methanol (0.63 g, 4.0 mmol). Workup and 
chromatographic purification (hexanes) afforded the title compound as a colorless solid (1.1 
g, 88%). m.p. 32–33 °C. 1H NMR (400 MHz, CDCl3) δ 7.95 – 7.83 (m, 4 H), 7.58 – 7.53 
(m, 2 H), 7.51 (d, J = 8.7 Hz, 1 H), 5.54 (s, 2 H). 13C{1H} NMR (101 MHz, CDCl3) δ 159.6 
(t, J = 31.5 Hz), 133.6, 133.2, 130.9, 129.0, 128.4, 128.3, 127.9, 127.0, 126.8, 125.8, 108.9 
(t, J = 315.0 Hz), 70.1. 19F NMR (376 MHz, CDCl3) δ −60.68 (s, 2 F). HRMS (APCI–
hexane/PhMe): m/z [M]+ calcd for C13H9BrF2O2: 313.9754; found: 313.9763 (2.9 ppm). IR 
(film): 3056, 2964, 1774, 1508, 1375, 1296, 1171, 1124, 947, 854, 816, 750, 698 cm−1.
4-((Methylsulfonyl)oxy)benzyl 2-bromo-2,2-difluoroacetate (1j)—General 
Procedure A was followed using 4-(hydroxymethyl)phenyl methanesulfonate (1.4 g, 7.1 
mmol). Workup and chromatographic purification (hexanes/EtOAc, 1:0→4:1) afforded the 
title compound as a colorless solid (2.4 g, 95%). mp 48–49 °C. 1H NMR (400 MHz, CDCl3) 
δ 7.52 – 7.47 (m, 2 H), 7.38 – 7.33 (m, 2 H), 5.38 (s, 2 H), 3.19 (s, 3 H). 13C{1H} NMR 
(101 MHz, CDCl3) δ 159.4 (t, J = 31.7 Hz), 149.7, 132.9, 130.4, 122.6, 108.7 (t, J = 314.4 
Hz), 68.7, 37.7. 19F NMR (376 MHz, CDCl3) δ −60.79 (s, 2 F). HRMS (EI): m/z [M]+ calcd 
for C10H9BrF2O5S: 357.9322; found: 357.9329 (2.0 ppm). IR (film): 3033, 2941, 1774, 
1606, 1506, 1456, 1420, 1371, 1298, 1178, 1153, 1122, 970, 872, 835, 710, 679 cm−1.
4-((2-Bromo-2,2-difluoroacetoxy)methyl)phenyl benzoate (1k)—General 
Procedure A was followed using 4-(hydroxymethyl)phenyl benzoate (0.57 g, 2.5 mmol). 
Workup and chromatographic purification (hexanes/EtOAc, 1:0→9:1) afforded the title 
compound as a colorless solid (0.79 g, 82%). mp 65–66 °C. 1H NMR (400 MHz, CDCl3) δ 
8.27 – 8.18 (m, 2 H), 7.71 – 7.63 (m, 1 H), 7.58 – 7.46 (m, 4 H), 7.32 – 7.27 (m, 2 H), 5.39 
(s, 2 H). 13C{1H} NMR (101 MHz, CDCl3) δ 165.1, 159.5 (t, J = 31.6 Hz), 151.7, 133.9, 
131.2, 130.3, 130.1, 129.3, 128.8, 122.4, 108.8 (t, J = 314.3 Hz), 69.2. 19F NMR (376 MHz, 
CDCl3) δ −60.74 (s, 2 F). HRMS (EI): m/z [M]+ calcd for C16H11BrF2O4: 383.9809; found: 
383.9810 (0.3 ppm). IR (film): 3065, 1776, 1740, 1601, 1510, 1452, 1379, 1298, 1265, 
1204, 1123, 1061, 1024, 951, 876, 804, 706, 604 cm−1.
3-Phenoxybenzyl 2-bromo-2,2-difluoroacetate (1l)—General Procedure A was 
followed using (3-phenoxyphenyl)methanol (0.69 g, 3.4 mmol). Workup and 
chromatographic purification (hexanes/EtOAc, 1:0→19:1) afforded the title compound as a 
colorless oil (0.99 g, 80%). 1H NMR (400 MHz, CDCl3) δ 7.40 – 7.34 (m, 3 H), 7.18 – 7.10 
(m, 2 H), 7.07 – 7.00 (m, 4 H), 5.33 (s, 2 H). 13C{1H} NMR (101 MHz, CDCl3) δ 159.5 (t, J 
= 31.6 Hz), 158.0, 156.7, 135.4, 130.4, 130.0, 123.9, 122.9, 119.5, 119.3, 118.3, 108.7 (t, J = 
314.4 Hz), 69.2. 19F NMR (376 MHz, CDCl3) δ −60.83 (s, 2 F). HRMS (APCI–hexane/
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PhMe): m/z [M]+ calcd for C15H11BrF2O3: 355.9860; found: 355.9845 (4.2 ppm). IR (film): 
3065, 3040, 2964, 1778, 1585, 1489, 1448, 1377, 1301, 1259, 1213, 1173, 1122, 945, 874, 
847, 777, 692, 604 cm−1.
3-Benzoylbenzyl 2-bromo-2,2-difluoroacetate (1m)—General Procedure A was 
followed using (3-(hydroxylmethyl)phenyl)(phenyl)methanone. Workup and 
chromatographic purification (hexanes/EtOAc, 1:0→21:4) afforded the title compound as a 
pale yellow oil (1.6 g, 88%). 1H NMR (400 MHz, CDCl3) δ 7.88 – 7.77 (m, 4 H), 7.67 – 
7.59 (m, 2 H), 7.58 – 7.47 (m, 3 H), 5.43 (s, 2 H). 13C{1H} NMR (101 MHz, CDCl3) δ 
196.1, 159.4 (t, J = 31.5 Hz), 138.3, 137.3, 133.9, 132.9, 132.3, 130.9, 130.2, 130.0, 129.1, 
128.5, 108.7 (t, J = 314.3 Hz), 69.2. 19F NMR (376 MHz, CDCl3) δ −60.81 (s, 2 F). HRMS 
(APCI–hexane/PhMe): m/z [M+H]+ calcd for C16H12BrF2O3: 368.9938; found: 368.9936 
(0.5 ppm). IR (film): 3065, 3040, 2964, 1778, 1585, 1489, 1448, 1377, 1301, 1259, 1213, 
1173, 1122, 945, 874, 847, 777, 692, 604 cm−1.
Methyl 4-((2-bromo-2,2-difluoroacetoxy)methyl)benzoate (1n)—General 
Procedure A was followed using methyl 4-(hydroxymethyl) benzoate (0.55 g, 3.3 mmol). 
Workup and chromatographic purification (hexanes/EtOAc, 1:0→19:1) afforded the title 
compound as a colorless oil (0.91 g, 85%). 1H NMR (400 MHz, CDCl3) δ 8.08 (d, J = 7.9 
Hz, 2 H), 7.47 (d, J = 8.0 Hz, 2 H), 5.41 (s, 2 H), 3.94 (s, 3 H). 13C{1H} NMR (101 MHz, 
CDCl3) δ 166.6, 159.4 (t, J = 31.7 Hz), 138.3, 130.9, 130.2, 128.1, 108.6 (t, J = 314.2 Hz), 
68.9, 52.4. 19F NMR (376 MHz, CDCl3) δ −60.86 (s, 2 F). HRMS (APCI–hexane/PhMe): 
m/z [M]+ calcd for C11H9BrF2O4: 321.9652; found: 321.9639 (4.0 ppm). IR (film): 2955, 
1778, 1724, 1616, 1437, 1379, 1283, 1171, 1111, 1020, 955, 847, 756, 708, 602 cm−1.
Tert-butyl 3-((2-bromo-2,2-difluoroacetoxy)methyl)-1H-indole-1-carboxylate 
(1o)—General Procedure A was followed using tert-butyl 3-(hydroxymethyl)-1H-indole-1-
carboxylate (1.2 g, 3.0 mmol). Workup and chromatographic purification (hexanes/EtOAc, 
1:0→9:1) afforded the title compound as a colorless solid (0.91 g, 85%). mp 47–49 °C. 1H 
NMR (400 MHz, CDCl3) δ 8.18 (d, J = 8.3 Hz, 1 H), 7.77 (s, 1 H), 7.64 (dt, J = 7.8, 1.0 Hz, 
1 H), 7.39 (ddd, J = 8.5, 7.2, 1.3 Hz, 1 H), 7.31 (td, J = 7.6, 1.1 Hz, 1 H), 5.54 (d, J = 0.7 
Hz, 2 H), 1.69 (s, 9 H). 13C{1H} NMR (126 MHz, CDCl3) δ 159.7 (t, J = 31.5 Hz), 149.5, 
135.7, 128.9, 127.1, 125.2, 123.3, 119.2, 115.6, 113.3, 108.8 (t, J = 314.5 Hz), 84.5, 62.0, 
28.3. 19F NMR (376 MHz, CDCl3) δ −60.7 (s, 2 F). HRMS (APCI–hexane/PhMe): m/z [M]+ 
calcd for C16H16BrF2NO4: 403.0231; found: 403.0222 (2.2 ppm). IR (film): 3126, 3055, 
2980, 2934, 1774, 1736, 1610, 1597, 1572, 1452, 1389, 1371, 1358, 1292, 1273, 1259, 
1231, 1159, 1128, 1092, 1020, 945, 854, 768, 746, 704 cm−1.
(1-Phenyl-1H-pyrazol-4-yl)methyl 2-bromo-2,2-difluoroacetate (1p)—General 
Procedure A was followed using (1-phenyl-1H-pyrazol-4-yl)methanol16 (0.87 g, 5.0 mmol). 
Workup and chromatographic purification (hexanes/EtOAc, 1:0→4:1) afforded the title 
compound as a colorless solid (1.5 g, 89%). mp 60–61 °C. 1H NMR (400 MHz, CDCl3) δ 
8.07 (s, 1 H), 7.81 (s, 1 H), 7.71 – 7.66 (m, 2 H), 7.51 – 7.44 (m, 2 H), 7.36 – 7.30 (m, 1 H), 
5.36 (s, 2 H). 13C{1H} NMR (101 MHz, CDCl3) δ 159.7 (t, J = 31.7 Hz), 141.7, 139.8, 
129.7, 128.2, 127.2, 119.5, 116.0, 108.9 (t, J = 314.5 Hz), 61.0. 19F NMR (376 MHz, 
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CDCl3) δ −60.90 (s, 2 F). HRMS (ESI): m/z [M + H]+ calcd for C12H10BrF2N2O2: 
330.9781; found: 330.9788 (2.1 ppm). IR (film): 3057, 2970, 1774, 1514, 1489, 1375, 1292, 
11689, 1122, 1067, 943, 887, 842, 771, 736, 692, 660 cm−1.
(2-Phenylfuran-3-yl)methyl 2-bromo-2,2-difluoroacetate (1q)—General Procedure 
A was followed using (2-phenylfuran-3-yl)methanol17 (0.52 g, 3.0 mmol). Workup provided 
the title compound as a yellow oil (0.93 g, 93%). 1H NMR (400 MHz, CDCl3) δ 7.66 – 7.59 
(m, 2 H), 7.51 – 7.45 (m, 3 H), 7.43 – 7.37 (m, 1 H), 6.61 (d, J = 1.9 Hz, 1 H), 5.40 (s, 2 
H). 13C{1H} NMR (101 MHz, CDCl3) δ 159.7 (t, J = 31.6 Hz), 153.4, 142.1, 129.9, 129.1, 
128.7, 126.6, 113.56, 113.54, 108.8 (t, J = 314.6 Hz), 62.6. 19F NMR (376 MHz, CDCl3) δ 
−60.75 (s, 2 F). HRMS (EI): m/z [M]+ calcd for C13H9BrF2O3: 329.9703; found: 329.9701 
(0.6 ppm). IR (film): 3057, 2970, 1774, 1514, 1489, 1375, 1292, 11689, 1122, 1067, 943, 
887, 842, 771, 736, 692, 660 cm−1.
Dibenzo[b,d]thiophen-4-ylmethyl 2-bromo-2,2-difluoroacetate (1r)—General 
Procedure A was followed using dibenzo[b,d]thiophen-4-ylmethanol (1.2 g, 5.6 mmol). 
Workup and chromatographic purification (hexanes) provided the title compound as a 
colorless solid (1.9 g, 89%). mp 90–91 °C. 1H NMR (400 MHz, CDCl3) δ 8.22 – 8.15 (m, 2 
H), 7.94 – 7.86 (m, 1 H), 7.57 – 7.47 (m, 4 H), 5.63 (s, 2 H). 13C{1H} NMR (101 MHz, 
CDCl3) δ 159.6 (t, J = 31.7 Hz), 139.24, 139.15, 136.6, 135.4, 127.7, 127.37, 127.33, 
124.90, 124.86, 123.0, 122.6, 122.0, 108.7 (t, J = 314.5 Hz), 68.7. 19F NMR (376 MHz, 
CDCl3) δ −60.52 (s, 2 F). HRMS (APCI–hexane/PhMe): m/z [M]+ calcd for C15H9BrF2O2S: 
369.9475; found: 369.9471 (1.1 ppm). IR (film): 3064, 2931, 1778, 1585, 1443, 1408, 1298, 
1180, 1136, 1047, 982, 941, 883, 827, 789, 746, 710, 669 cm−1.
(1-(Methylsulfonyl)-1H-indol-2-yl)methyl 2-bromo-2,2-difluoroacetate (1s)—
General Procedure A was followed using [1-(methylsulfonyl)-1H-indol-2-yl]methanol18 (1.1 
g, 5.0 mmol). Workup and chromatographic purification (hexanes/EtOAc 1:0→9:1) 
provided the title compound as a grey solid (1.1 g, 70%). mp 87–88 °C. 1H NMR (400 MHz, 
CDCl3) δ 8.05 (dt, J = 8.3, 1.0 Hz, 1 H), 7.66 – 7.61 (m, 1 H), 7.47 – 7.40 (m, 1 H), 7.38 – 
7.31 (m, 1 H), 6.91 (s, 1 H), 5.69 (s, 2 H), 3.19 (s, 3H). 13C{1H} NMR (101 MHz, CDCl3) δ 
158.8 (t, J = 31.7 Hz), 137.2, 131.7, 128.3, 126.5, 124.3, 122.0, 114.8, 114.1, 108.7 (t, J = 
314.3 Hz), 62.7, 41.1. 19F NMR (376 MHz, CDCl3) δ −60.63 (s, 2 F). HRMS (APCI–
hexane/PhMe): m/z [M]+ calcd for C12H10BrF2NO4S: 380.9482; found: 380.9479 (0.8 
ppm). IR (film): 3028, 1778, 1452, 1369, 1292, 1175, 1121, 964, 916, 823, 771, 748, 719, 
685 cm−1.
(5-(Furan-2-yl)-1-methyl-1H-pyrazol-3-yl)methyl 2-bromo-2,2-difluoroacetate 
(3a)—HO2CCF2Br (0.27 g, 1.5 mmol) was added to a round-bottom flask, which was 
sealed with a rubber septum and attached to an oil bubbler. DCM (6.0 mL) and DMF (0.30 
mL) were injected, and the solution was cooled to −10 °C. Oxalyl chloride (0.13 mL, 1.5 
mmol) was injected (caution: evolution of noxious gas), and after 5 min, the mixture was 
allowed to warm to rt. After 2 h, the mixture was cooled to –10 °C, and a solution of [5-
(furan-2-yl)-1-methyl-1H-pyrazol-3-yl]methanol13 (0.19 g, 1.0 mmol) and NEt3 (0.38 mL, 
2.7 mmol) in DCM (1.5 mL) was added. After 2.5 h, the reaction was quenched with water, 
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and the aqueous layer was extracted with EtOAc (4 × 10 mL). The combined organic layers 
were washed with brine, dried over Na2SO4, and filtered. Chromatographic purification 
(hexanes/EtOAc 1:0→3:2) provided the title compound as a yellow solid (0.29 g, 82%). 
m.p. 39–40 °C. 1H NMR (400 MHz, CDCl3) δ 7.54 – 7.52 (m, 1 H), 6.59 (d, J = 3.4 Hz, 1 
H), 6.57 (s, 1 H), 6.52 (dd, J = 3.4, 1.8 Hz, 1 H), 5.36 (s, 2 H), 4.05 (s, 3 H). 13C{1H} NMR 
(101 MHz, CDCl3) δ 159.6 (t, J = 31.6 Hz), 144.4, 144.2, 143.1, 135.7, 111.7, 109.1, 108.8 
(t, J = 314.9 Hz), 105.4, 63.5, 39.0. 19F NMR (376 MHz, CDCl3) δ −60.64 (s, 2 F). HRMS 
(APCI–hexane/PhMe): m/z [M + Na]+ calcd for C11H9BrF2N2O3Na: 356.9662; found: 
356.9648 (3.9 ppm). IR (film): 3128, 1776, 1531, 1475, 1448, 1362, 1302, 1163, 1124, 
1011, 947, 903, 885, 800, 741, 702 cm−1.
General Procedure B (solid substrates)
An oven-dried 15 mL screw-top vial was sealed with a PTFE septum and cooled under an 
atmosphere of dry N2. CuI (9.5 mg, 0.050 mmol) and (hetero)benzyl bromodifluoroacetate 
(0.25 mmol) were added to the vial, which was transferred into a N2-filled glovebox. 
Anhydrous KF (58.1 mg, 1.00 mmol) and anhydrous KI (10.4 mg, 0.0625 mmol) were 
added to the vial, which was sealed with a PTFE septum and removed from the glovebox. 
MeCN (125 µL), MeO2CCF2Br (11.0 µL, 0.100 mmol) and DMF (125 µL) were injected 
into the vial, which was placed in a pre-heated hot plate (70 °C) and stirred for 24 h. After 
cooling to room temperature, the mixture was diluted with EtOAc or Et2O (25 mL). The 
mixture was washed with H2O (20 mL) and brine (20 mL). The organic phase was dried 
over Na2SO4, filtered, and the solvent was removed in vacuo. The residue was purified via 
silica gel chromatography to provide the corresponding trifluoroethyl(hetero)arene.
General Procedure C (liquid substrates)
An oven-dried 15 mL screw-top vial was sealed with a PTFE septum and cooled under an 
atmosphere of dry N2. CuI (9.5 mg, 0.050 mmol) was added to the vial, which was 
transferred into a N2-filled glovebox. Anhydrous KF (58.1 mg, 1.00 mmol) and anhydrous 
KI (10.4 mg, 0.0625 mmol) were added to the vial, which was sealed with a PTFE septum 
and removed from the glovebox. MeCN (125 µL), MeO2CCF2Br (11.0 µL, 0.100 mmol), 
(hetero)benzyl bromodifluoroacetate (0.25 mmol), and DMF (125 µL) were injected into the 
vial, which was placed in a pre-heated hot plate (70 °C) and stirred for 24 h. After cooling to 
room temperature, the mixture was diluted with EtOAc or Et2O (25 mL). The mixture was 
washed with H2O (20 mL) and brine (20 mL). The organic phase was dried over Na2SO4, 
filtered, and the solvent was removed in vacuo. The residue was purified via silica gel 
chromatography to provide the corresponding trifluoroethyl(hetero)arene.
Synthesis of Trifluoroethyl(hetero)arenes
Each decarboxylative trifluoromethylation was run twice, and the yields in manuscript refer 
to the average of two runs. The procedures described below represent one individual run. 
ArCH2CF2CF3 was observed as a minor side-product (<2%) in many reactions, as 
evidenced by 19F NMR spectroscopy (δ −85 (s, 3 F), −117 (t, J = 18 Hz, 2 F).
1-(Benzyloxy)-4-(2,2,2-trifluoroethyl)benzene (2b)—General Procedure B was 
followed using 1b (92.8 mg, 0.250 mmol). Workup and chromatographic purification 
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(hexanes/Et2O 39:1) afforded the title compound as a colorless solid (55.7 mg, 84%). mp 
78–79 °C (lit.19 82–84 °C). 1H NMR (400 MHz, CDCl3) δ 7.48–7.39 (m, 4 H), 7.39–7.33 
(m, 1 H), 7.27–7.21 (m, 2 H), 7.01–6.96 (m, 2 H), 5.09 (s, 2 H), 3.33 (q, J = 10.8 Hz, 2 
H). 19F NMR (376 MHz, CDCl3) δ −66.4 (3 F, t, J = 10.9 Hz). Spectroscopic data are 
consistent with the previous report.19
Gram-scale Decarboxylative Trifluoromethylation: An oven-dried 25 mL Schlenk flask 
was sealed with a rubber septum and cooled under an atmosphere of dry N2. CuI (0.23 g, 1.2 
mmol) was added to the vial, which was transferred into a N2-filled glovebox. Anhydrous 
KF (1.4 g, 24 mmol) and anhydrous KI (0.25 g, 1.5 mmol) were added to the flask, which 
was sealed with a rubber septum and removed from the glovebox. The flask was attached to 
a Schlenk line, and remained open to an atmosphere of dry N2 for the remainder of the 
reaction (CAUTION: CO2 (g) is generated during the course of the reaction; therefore, the 
reaction should either be conducted in a pressure-rated vessel, or open to an inert 
atmosphere). MeCN (3.0 mL), MeO2CCF2Br (0.26 mL, 2.4 mmol), 1b (2.2 g, 6.0 mmol), 
and DMF (3.0 mL) were injected into the flask, which was placed in a pre-heated oil bath 
(70 °C) and stirred for 24 h. After cooling to room temperature, the mixture was diluted with 
EtOAc (75 mL). The mixture was washed with H2O (75 mL) and brine (75 mL). The 
organic phase was dried over Na2SO4, filtered, and the solvent was removed in vacuo. The 
residue was purified via silica gel chromatography (hexanes/Et2O 39:1) to provide 2b as a 
colorless solid (1.4 g, 87%). The 1H and 19F NMR spectrum were consistent with the data 
described above.
N-(4-(2,2,2-Trifluoroethyl)phenyl)pivalamide (2c)—General Procedure B was 
followed using 1c (91.0 mg, 0.250 mmol). Workup and chromatographic purification 
(hexanes/EtOAc 1:0→9:1) afforded the title compound as a colorless solid (52.8 mg, 81%). 
mp 132–133 °C. 1H NMR (400 MHz, CDCl3) δ 7.54 (d, J = 8.4 Hz, 2 H), 7.37 (s, 1 H), 7.25 
(d, J = 8.3 Hz, 2 H), 3.33 (q, J = 10.8 Hz, 2 H), 1.32 (s, 9 H). 13C{1H} NMR (101 MHz, 
CDCl3) δ 176.8, 138.1, 130.8, 125.9 (q, J = 3.0 Hz), 125.8 (q, J = 276.7 Hz), 120.2, 39.76, 
39.74 (q, J = 29.8 Hz), 27.7. 19F NMR (376 MHz, CDCl3) δ −65.65 (t, J = 10.8 Hz, 3 F). 
HRMS (EI): m/z [M]+ calcd for C13H16F3NO: 259.1184; found: 259.1189 (1.9 ppm). IR 
(film): 3317, 2978, 2873, 1654, 1599, 1522, 1412, 1315, 1265, 1244, 1138, 1072, 905, 806, 
698, 656 cm−1.
N,N-Dibenzyl-3-(2,2,2-trifluoroethyl)aniline (2d)—General Procedure B was followed 
using 1d (115 mg, 0.250 mmol). Workup and chromatographic purification (hexanes/DCM 
1:0→17:3) afforded the title compound as a colorless oil (80.6 mg, 91%). 1H NMR (400 
MHz, CDCl3) δ 7.40 – 7.33 (m, 4 H), 7.32 – 7.25 (m, 6 H), 7.17 (t, J = 7.9 Hz, 1 H), 6.73 
(dd, J = 8.4, 2.7 Hz, 1 H), 6.70 – 6.64 (m, 2 H), 4.68 (s, 4 H), 3.26 (q, J = 11.0 Hz, 2 
H). 13C{1H} NMR (101 MHz, CDCl3) δ 149.6, 138.4, 131.2 (q, J = 2.8 Hz), 129.6, 128.8, 
127.1, 126.8, 126.0 (q, J = 277.0 Hz), 118.6, 114.3, 112.3, 54.3, 40.7 (q, J = 29.5 Hz). 19F 
NMR (376 MHz, CDCl3) δ −65.68 (t, J = 10.9 Hz, 3 F). HRMS (EI): m/z [M]+ calcd for 
C22H20F3N: 355.1548; found: 355.1561 (3.7 ppm). IR (film): 3061, 3030, 2922, 2860, 1605, 
1582, 1499, 1452, 1358, 1259, 1132, 1078, 1028, 991, 964, 922, 777, 729, 696 cm−1.
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2-Bromo-3,4-dimethoxy-1-(2,2,2-trifluoroethyl)benzene (2e)—General Procedure 
C was followed using 1e (101 mg, 0.250 mmol). Workup and chromatographic purification 
(hexanes/DCM 1:0→17:3) afforded the title compound as a colorless oil (57.9 mg, 78%). 1H 
NMR (400 MHz, CDCl3) δ 7.10 (d, J = 8.5 Hz, 1 H), 6.87 (d, J = 8.6 Hz, 1 H), 3.88 (s, 3 H), 
3.86 (s, 3 H), 3.60 (q, J = 10.6 Hz, 2 H). 19F NMR (376 MHz, CDCl3) δ −65.48 (t, J = 10.5 
Hz, 3 F). Spectroscopic data are consistent with the previous report.4a
1-(Benzyloxy)-2-(2,2,2-trifluoroethyl)benzene (2f)—General Procedure B was 
followed using 1f (92.8 mg, 0.250 mmol). Workup and chromatographic purification 
(hexanes/DCM 1:0→19:1) afforded the title compound as a colorless oil (50.7 mg, 76%). 1H 
NMR (400 MHz, CDCl3) δ 7.54 – 7.30 (m, 7 H), 7.07 – 6.93 (m, 2 H), 5.15 (s, 2 H), 3.57 (q, 
J = 11.0 Hz, 2 H). 13C{1H} NMR (101 MHz, CDCl3) δ 157.2, 137.0, 132.0, 129.6, 128.7, 
128.1, 127.3, 126.3 (q, J = 277.3 Hz), 120.9, 119.3 (q, J = 2.8 Hz), 112.2, 70.3, 33.7 (q, J = 
30.2 Hz). 19F NMR (376 MHz, CDCl3) δ −65.34 (t, J = 10.9 Hz, 3 F). HRMS (EI): m/z [M]+ 
calcd for C15H13F3O: 266.0918; found: 266.0920 (0.8 ppm). IR (film): 3005, 2943, 1595, 
1494, 1406, 1360, 1285, 1246, 1138, 1092, 1036, 947, 901, 806, 766, 681, 646 cm−1.
1,3,5-Trimethyl-2-(2,2,2-trifluoroethyl)benzene (2g)—General Procedure C was 
followed using 1g (76.8 mg, 0.250 mmol). Workup and chromatographic purification 
(hexanes) afforded the title compound as a colorless oil (22.4 mg, 46%). 1H NMR (400 
MHz, CDCl3) δ 6.91 (s, 2 H), 3.48 (q, J = 10.8 Hz, 2 H), 2.35 (s, 6 H), 2.29 (s, 3 
H). 13C{1H} NMR (126 MHz, CDCl3) δ 138.3, 137.7, 129.4, 126.9 (q, J = 278.3 Hz), 125.6 
(q, J = 2.47 Hz), 33.6 (q, J = 29.6 Hz), 21.0, 20.4 (q, J = 2.1 Hz). 19F NMR (376 MHz, 
CDCl3) δ −63.8 (t, J = 10.8 Hz, 3 F). HRMS (EI): m/z [M]+ calcd for C11H13F3: 202.0969; 
found: 202.0978 (4.5 ppm). IR (film): 3007, 2964, 2926, 2868, 2856, 1614, 1481, 1450, 
1427, 1381, 1352, 1306, 1248, 1202, 1130, 1099, 1026, 941, 910, 854, 833, 804, 735, 654 
cm−1.
(E)-1-Styryl-4-(2,2,2-trifluoroethyl)benzene (2h)—General Procedure B was followed 
using 1h (91.8 mg, 0.250 mmol). Workup and chromatographic purification (hexanes/
EtOAc 1:0→9:1) afforded the title compound as a colorless solid (39.2 mg, 60%). mp 135–
136 °C. 1H NMR (400 MHz, CDCl3) δ 7.59 – 7.51 (m, 4 H), 7.41 (t, J = 7.5 Hz, 2 H), 7.36 – 
7.29 (m, 3 H), 7.17 – 7.14 (m, 2 H), 3.40 (q, J = 10.8 Hz, 2 H). 13C{1H} NMR (101 MHz, 
CDCl3) δ 137.4, 137.2, 130.6, 129.45 (q, J = 2.9 Hz), 129.41, 128.8, 128.0, 127.9, 126.8, 
126.7, 125.9 (q, J = 276.9 Hz), 40.1 (q, J = 29.8 Hz). 19F NMR (376 MHz, CDCl3) δ −65.81 
(t, J = 10.8 Hz, 3 F). HRMS (EI): m/z [M]+ calcd for C16H13F3: 262.0969; found: 262.0968 
(0.4 ppm). IR (film): 3022, 1448, 1429, 1420, 1356, 1258, 1147, 1119, 1078, 964, 908, 820, 
792, 754, 739, 692, 658 cm−1.
2-(2,2,2-Trifluoroethyl)naphthalene (2i)—General Procedure B was followed using 1i 
(78.8 mg, 0.250 mmol). Workup and chromatographic purification (hexanes) afforded the 
title compound as a colorless solid (42.3 mg, 81%). mp 51–53 °C. 1H NMR (400 MHz, 
CDCl3) δ 7.90 – 7.81 (m, 3 H), 7.79 (s, 1 H), 7.55 – 7.48 (m, 2 H), 7.42 (d, J = 8.4 Hz, 1 H), 
3.55 (q, J = 10.8 Hz, 2 H). 19F NMR (376 MHz, CDCl3) δ −65.65 (t, J = 10.8 Hz, 3 F). 
Spectroscopic data are consistent with the previous report.4b
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4-(2,2,2-Trifluoroethyl)phenyl methanesulfonate (2j)—General Procedure B was 
followed using 1j (89.8 mg, 0.250 mmol). Workup and chromatographic purification 
(hexanes/DCM 1:0→2:3) afforded the title compound as a colorless solid (43.5 mg, 69%). 
mp 75–76 °C. 1H NMR (400 MHz, CDCl3) δ 7.36 (d, J = 8.5 Hz, 2 H), 7.29 (d, J = 8.6 Hz, 
2 H), 3.39 (q, J = 10.7 Hz, 2 H), 3.15 (s, 3 H). 13C{1H} NMR (101 MHz, CDCl3) δ 149.1, 
132.0, 129.6 (q, J = 3.0 Hz), 125.6 (q, J = 276.8 Hz), 122.4, 39.6 (q, J = 30.1 Hz), 37.5. 19F 
NMR (376 MHz, CDCl3) δ −65.36 (t, J = 10.7 Hz, 3 F). HRMS (EI): m/z [M]+ calcd for 
C9H9F3O3S: 254.0225; found: 254.0229 (1.6 ppm). IR (film): 3031, 2945, 1608, 1502, 
1456, 1421, 1361, 1302, 1177, 1153, 1132, 974, 876, 832, 707, 681 cm−1.
4-(2,2,2-Trifluoroethyl)phenyl benzoate (2k)—General Procedure B was followed 
using 1k (96.3 mg, 0.250 mmol). Workup and chromatographic purification (hexanes/
EtOAc 1:0→19:1) afforded the title compound as a colorless solid (49.6 mg, 71%). mp 84–
85 °C. 1H NMR (400 MHz, CDCl3) δ 8.25 (d, J = 7.6 Hz, 2 H), 7.68 (t, J = 7.4 Hz, 1 H), 
7.55 (t, J = 7.7 Hz, 2 H), 7.40 (d, J = 8.3 Hz, 2 H), 7.26 (d, J = 8.3 Hz, 2 H), 3.43 (q, J = 
10.8 Hz, 2 H). 19F NMR (376 MHz, CDCl3) δ −66.37 (t, J = 10.8 Hz, 3 F). Spectroscopic 
data are consistent with the previous report.20
1-Phenoxy-3-(2,2,2-trifluoroethyl)benzene (2l)—General Procedure C was followed 
using 1l (89.3 mg, 0.250 mmol). Workup and chromatographic purification (hexanes/DCM 
1:0→19:1) afforded the title compound as a colorless oil (41.9 mg, 67%). 1H NMR (400 
MHz, CDCl3) δ 7.41 – 7.29 (m, 3 H), 7.14 (t, J = 7.4 Hz, 1 H), 7.09 – 6.95 (m, 5 H), 3.35 (q, 
J = 10.8 Hz, 2 H). 19F NMR (376 MHz, CDCl3) δ −65.46 (t, J = 10.8 Hz, 3 F). 
Spectroscopic data are consistent with the previous report.5l
Phenyl(3-(2,2,2-trifluoroethyl)phenyl)methanone (2m)—General Procedure C was 
followed using 1m (92.3 mg, 0.250 mmol). Workup and chromatographic purification 
(hexanes/DCM 1:0→3:1) afforded the title compound as a colorless oil (40.9 mg, 62%). 1H 
NMR (400 MHz, CDCl3) δ 7.85 – 7.71 (m, 4 H), 7.62 (t, J = 7.4 Hz, 1 H), 7.57 – 7.45 (m, 4 
H), 3.45 (q, J = 10.7 Hz, 2 H). 13C{1H} NMR (101 MHz, CDCl3) δ 196.3, 138.2, 137.4, 
134.2, 132.8, 131.8, 130.6 (q, J = 2.9 Hz), 130.2, 130.0, 128.8, 128.5, 125.7 (q, J = 276.9 
Hz), 40.2 (q, J = 29.8 Hz). 19F NMR (376 MHz, CDCl3) δ −65.66 (t, J = 10.7 Hz, 3 F). 
HRMS (EI): m/z [M]+ calcd for C15H11F3O: 264.0762; found: 264.0763 (0.4 ppm). IR 
(film): 3063, 3036, 2947, 1661, 1597, 1585, 1578, 1448, 1362, 1319, 1308, 1288, 1256, 
1209, 1138, 1101, 1076, 986, 968, 932, 906, 870, 852, 813, 783, 714, 640, 602 cm−1.
Methyl 4-(2,2,2-trifluoroethyl)benzoate (2n)—General Procedure C was followed 
using 1n (80.8 mg, 0.250 mmol). Workup and chromatographic purification (hexanes/
EtOAc 1:0→9:1) afforded the title compound as a colorless oil [(29.5 mg, 51% (after 
correction for 5 mol% ArCH2Br side-product)]. 1H NMR (400 MHz, CDCl3) δ 8.07 – 8.02 
(m, 2 H), 7.39 (d, J = 8.1 Hz, 2 H), 3.93 (s, 3 H), 3.44 (q, J = 10.7 Hz, 2 H). 19F NMR (376 
MHz, CDCl3) δ −65.58 (t, J = 10.7 Hz, 3 F). Spectroscopic data are consistent with the 
previous report.4b
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Tert-butyl 3-(2,2,2-trifluoroethyl)-1H-indole-1-carboxylate (2o)—General 
Procedure B was followed using 1o (101 mg, 0.250 mmol). Workup and chromatographic 
purification (hexanes/EtOAc, 39:1) afforded the title compound as a colorless solid (58.1 
mg, 78%). m.p. 79–80 °C. 1H NMR (500 MHz, CDCl3) δ 8.17 (d, J = 6.7 Hz, 1 H), 7.61 (s, 
1 H), 7.56 (d, J = 7.8 Hz, 1 H), 7.37 (ddd, J = 8.4, 7.2, 1.3 Hz, 1 H), 7.30 (ddd, J = 8.1, 7.3, 
1.1 Hz, 1 H), 3.51 (qd, J = 10.6, 0.9 Hz, 2 H), 1.69 (s, 9 H). 13C{1H} NMR (126 MHz, 
CDCl3) δ 149.6, 135.4, 130.0, 125.93 (q, J = 276.9 Hz), 125.92, 124.9, 123.0, 119.0, 115.5, 
109.5 (q, J = 3.3 Hz), 84.2, 30.5 (q, J = 31.7 Hz), 28.3. 19F NMR (376 MHz, CDCl3) δ 
−65.57 (t, J = 10.7 Hz, 3 F). HRMS (EI): m/z [M]+ calcd for C15H16F3NO2: 299.1133; 
found: 299.1122 (3.7 ppm). IR (film): 3057, 2982, 2934, 1736, 1452, 1375, 1350, 1277, 
1259, 1229, 1153, 1138, 1101, 1016, 914, 856, 770, 744 cm−1.
1-Phenyl-4-(2,2,2-trifluoroethyl)-1H-pyrazole (2p)—General Procedure B was 
followed using 1p (82.8 mg, 0.250 mmol). Workup and chromatographic purification 
(hexanes/EtOAc 1:0→9:1) afforded the title compound as a colorless solid (47.2 mg, 83%). 
m.p. 45–46 °C. 1H NMR (500 MHz, CDCl3) δ 7.90 (s, 1 H), 7.70 – 7.65 (m, 3 H), 7.49 – 
7.42 (m, 2 H), 7.33 – 7.28 (m, 1 H), 3.36 (q, J = 10.7 Hz, 2 H). 13C{1H} NMR (126 MHz, 
CDCl3) δ 141.6, 140.0, 129.6, 127.0, 126.9, 125.7 (q, J = 276.2 Hz), 119.3, 111.8 (q, J = 3.3 
Hz), 30.1 (q, J = 31.7 Hz). 19F NMR (376 MHz, CDCl3) δ −66.02 (t, J = 10.7 Hz, 3 F). 
HRMS (ESI): m/z [M + H]+ calcd for C11H10F3N2: 227.0796; found: 227.0794 (0.9 ppm). 
IR (film): 3153, 3109, 3053, 2943, 1601, 1576, 1506, 1464, 1404, 1387, 1348, 1259, 1213, 
1138, 1084, 1043, 1018, 955, 906, 862, 835, 808, 756, 692, 660 cm−1.
2-Phenyl-3-(2,2,2-trifluoroethyl)furan (2q)—General Procedure C was followed using 
1q (82.8 mg, 0.250 mmol). Workup and chromatographic purification (hexanes/EtOAc 
1:0→19:1) afforded the title compound as a colorless oil (31.2 mg, 55%). 1H NMR (500 
MHz, CDCl3) δ 7.61 – 7.57 (m, 2 H), 7.51 – 7.44 (m, 3 H), 7.41 – 7.36 (m, 1 H), 6.53 (s, 1 
H), 3.45 (q, J = 10.5 Hz, 2 H). 13C{1H} NMR (126 MHz, CDCl3) δ 152.1, 142.0, 130.5, 
128.9, 128.3, 126.8, 126.1 (q, J = 277.0 Hz), 113.5, 109.8 (q, J = 3.3 Hz), 31.3 (q, J = 31.0 
Hz). 19F NMR (376 MHz, CDCl3) δ −66.81 (t, J = 10.7 Hz, 3 F). HRMS (EI): m/z [M]+ 
calcd for C12H9F3O: 226.0605; found: 226.0597 (3.5 ppm). IR (film) 3055, 2937, 2856, 
1599, 1487, 1447, 1433, 1362, 1298, 1273, 1254, 1140, 1105, 1082, 1053, 1032, 908, 887, 
835, 764, 743, 692, 671, 650, 604 cm−1.
4-(2,2,2-Trifluoroethyl)dibenzo[b,d]thiophenes (2r)—General Procedure B was 
followed using 1r (92.8 mg, 0.250 mmol). Workup and chromatographic purification 
(hexanes/EtOAc 1:0→19:1) afforded the title compound as a colorless solid (40.9 mg, 61%). 
mp 102–103 °C (lit.19 104–106 °C). 1H NMR (400 MHz, CDCl3) δ 8.21 – 8.13 (m, 2 H), 
7.92 – 7.85 (m, 1 H), 7.54 – 7.42 (m, 4 H), 3.69 (q, J = 10.6 Hz, 2 H). 19F NMR (376 MHz, 
CDCl3) δ −64.65 (t, J = 10.6 Hz, 3 F). Spectroscopic data are consistent with the previous 
report.19
1-(Methylsulfonyl)-2-(2,2,2-trifluoroethyl)-1H-indole (2s)—General Procedure B 
was followed using 1s (95.5 mg, 0.250 mmol). Workup and chromatographic purification 
(hexanes/EtOAc 9:1→2:1) afforded the title compound as a colorless solid (42.6 mg, 61%). 
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m.p. 95–96 °C. 1H NMR (400 MHz, CDCl3) δ 8.03 – 7.99 (m, 1 H), 7.64 – 7.59 (m, 1 H), 
7.41 (ddd, J = 8.4, 7.2, 1.4 Hz, 1 H), 7.34 (td, J = 7.5, 1.1 Hz, 1 H), 6.80 (s, 1 H), 4.04 (q, J 
= 10.2 Hz, 2 H), 3.13 (s, 3 H). 13C{1H} NMR (101 MHz, CDCl3) δ 136.8, 129.4 (q, J = 3.5 
Hz), 129.0, 125.5, 125.2 (q, J = 277.1 Hz), 124.2, 121.3, 114.3, 113.1, 40.9, 32.8 (q, J = 31.7 
Hz). 19F NMR (376 MHz, CDCl3) δ −64.76 (t, J = 10.2 Hz, 3 F). HRMS (EI): m/z [M]+ 
calcd for C11H10F3NO2S: 277.0384; found: 277.0382 (0.7 ppm). IR (film) 3022, 2934, 
1452, 1366, 1331, 1304, 1275, 1254, 1234, 1175, 1153, 1082, 1057, 1022, 962, 924, 899, 
818, 771, 748, 727, 665, 636, 554, 513 cm−1.
5-(Furan-2-yl)-1-methyl-3-(2,2,2-trifluoroethyl)-1H-pyrazole (5)—General 
Procedure B was followed using 3a (83.8 mg, 0.250 mmol). Workup and chromatographic 
purification (hexanes/EtOAc 1:0→4:1) afforded the title compound as a yellow oil (42.6 
mg, 73%). 1H NMR (400 MHz, CDCl3) δ 7.51 (dd, J = 1.9, 0.8 Hz, 1 H), 6.57 (dd, J = 3.4, 
0.8 Hz, 1 H), 6.51 (dd, J = 3.4, 1.8 Hz, 1 H), 6.48 (s, 1 H), 4.02 (s, 3 H), 3.45 (q, J = 10.8 
Hz, 2 H). 19F NMR (376 MHz, CDCl3) δ −65.72 (t, J = 10.8 Hz). Spectroscopic data are 
consistent with the previous report.13
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Iodide plays an essential role in benzylic trifluoromethylation
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Trifluoromethylation of Benzylic Electrophiles Typically Requires Stoichiometric Copper
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Previously proposed mechanism involves generation of free −CF3
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Copper-catalyzed reaction improves access to target compounds
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Table 2
Copper-catalyzed decarboxylative trifluoromethylation tolerates important functional groups and 
heterocyclesa,b
a
0.25 mmol 1b–s, 0.050 mmol CuI, 0.063 mmol KI, 0.10 mmol MeO2CCF2Br, 1.0 mmol KF, 0.13 mL DMF, 0.13 mL MeCN;
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b
The yields represent the average of two independent experiments;
c
6.0 mmol scale, single experiment.
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